This work may not be copied, distributed, displayed, published, reproduced, transmitted, modified, posted, sold, licensed, or used for commercial purposes. By downloading this file, you are agreeing to the publisher’s Terms & Conditions.

Educational Activity

Effectiveness of Antipsychotic Drugs in Patients With Chronic Schizophrenia: Efficacy, Safety, and Cost Outcomes of CATIE and Other Trials

Jeffrey A. Lieberman, MD, Chair

Published: February 15, 2007

Article Abstract

After the introduction of clozapine in 1990,second-generation—or atypical—antipsychotics were thought to be more effective,safer, and less costly than first-generation—or typical—antipsychotics.However, only limited evidence on the efficacy and safety of atypicals wasavailable. Because of this knowledge gap, the National Institute of MentalHealth sponsored the Clinical Antipsychotic Trials of InterventionEffectiveness (CATIE) to compare first- and second-generation antipsychotics.The CATIE trial found that antipsychotic drug treatments are generallyeffective overall but have various limitations as reflected by high rates ofdiscontinuation due to both efficacy and tolerability problems. In addition,the trial found that conventional agents with intermediate potency werecomparably effective with atypical agents.

This CME activity is expired. For more CME activities, visit
Find more articles on this and other psychiatry and CNS topics:
The Journal of Clinical Psychiatry
The Primary Care Companion for CNS Disorders

Some JCP and PCC articles are available in PDF format only. Please click the PDF link at the top of this page to access the full text.

Related Articles

Volume: 68

Quick Links: